ArticleBMC rheumatology2026
Personalized exercise therapy during targeted drug therapy tapering in patients with rheumatoid arthritis: a pilot randomized controlled trial.
Article in BMC rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExercise therapy (ET) is a valuable adjunctive treatment for rheumatoid arthritis (RA). We hypothesized that ET supports maintenance of remission or low disease activity (LDA) during targeted drug therapy (TT) tapering. This pilot randomized controlled trial evaluated the feasibility, safety, and preliminary effects of individualized ET in RA patients undergoing TT tapering.
methodsThirty-two RA patients initiating TT tapering were randomized to receive personalized ET plus usual care (intervention group, n = 16) or usual care alone (control group, n = 16) for 16 weeks. The primary exploratory outcome was the proportion of patients maintaining remission or LDA (DAS28-ESR < 3.2) by week 16 without TT re-escalation. Secondary outcomes included DAS28-ESR and its component measurements at weeks 8 and 16, health-related quality of life at week 16 (SF-12), physical activity (IPAQ), and daily step count. Safety and adherence were also assessed.
resultsAll participants in the intervention group completed the 16-week ET program with high adherence. Remission or LDA was maintained in 75.0% (12/16) of patients in the intervention group and 81.3% (13/16) in the control group, with no clinically meaningful between-group difference. Although DAS28-ESR scores were comparable, a transient increase in physician visual analog scale was identified in the intervention group at week 8, which returned to the baseline by week 16. Over the 16-week period, IPAQ scores and step count tended to increase after adjustment for baseline values, whereas SF-12 mental health scores declined in the intervention group. No serious adverse events were observed.
conclusionsIn this pilot randomized controlled trial, individualized ET during TT tapering was safe and feasible. Nevertheless, transient increases in disease activity and declines in mental health indicate the need for careful clinical monitoring and psychological support. The study was not designed to evaluate efficacy outcomes and no clinically meaningful differences between the groups in remission maintenance were identified. Larger trials will be necessary to evaluate the efficacy and long-term safety of ET during TT tapering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.